The potential health impact and healthcare cost savings of different sodium reduction strategies in Canada

- Nadia Flexner^{1*}, Amanda C. Jones², Ben Amies-Cull³, Linda Cobiac⁴, Eduardo Nilson^{5,6}, Mary
 R. L'Abbe^{1*}
 - ¹Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
 - ²Department of Public Health, University of Otago, Wellington, New Zealand.
 - ³Nuffield Department of Primary Care Healthcare Sciences, University of Oxford, Oxford, United Kingdom.
 - ⁴Griffith University, Queensland, Australia.
 - ⁵Center for Epidemiological Research in Nutrition and Public Health, University of São Paulo, São Paulo, Brazil.
 - ⁶Oswaldo Cruz Foundation (Fiocruz/Brasilia), Brasilia, Brazil.

- 7 **Keywords:** sodium reduction, health impact, cardiovascular disease, cost-utility analysis, multi-
- 8 state lifetable model, food policy.

10 Abstract

9

1

2

6

11 Background

- High dietary sodium is the main dietary risk factor for non-communicable diseases due to its
- impact on cardiovascular diseases, the leading cause of death globally. The Government of
- 14 Canada has taken measures to reduce average dietary sodium intakes, such as setting voluntary
- sodium reduction targets for packaged foods and recently approving regulations mandating 'high
- in' front-of-pack labeling (FOPL) symbols.

17 Objectives

^{*}Corresponding authors: mary.labbe@utoronto.ca; nadia.flexner@mail.utoronto.ca

To estimate the number of avoidable ischemic heart disease (IHD) and stroke incidence cases. 18 and their associated healthcare cost and Quality-Adjusted Life Year (QALY) savings resulting 19 20 from different sodium reduction strategies and recommendations in Canada. Methods 21 22 We used the PRIMEtime model, a proportional multi-state lifetable model. Outcomes were 23 modeled over the lifetime of the population alive in 2019, at a 1.5% discount rate, and from the 24 public healthcare system perspective. Nationally representative data were used as inputs for the 25 model. **Results** 26 27 Fully meeting Health Canada's sodium reduction targets was estimated to prevent 219,490 (95% UI, 73,409–408,630) cases of IHD, and 164,435 (95% UI, 56,121–305,770) strokes. This led to a 28 gain of 276,185 (95% UI, 85,414-552,616) QALYs, and healthcare costs savings of CAD\$ 29 4,212(95% UI, 1,303–8,206) million over the lifetime of the 2019 cohort. Sodium reduction 30 intake through FOPL regulations has the potential to prevent between 35,930 (95% UI, 8,058– 31 32 80,528) and 124,744 (95% UI, 40,125–235,643) cases of IHD, and between 26,869 (95% UI, 5,235–61,621) and 93,129 (95% UI, 30,296–176,014) strokes. This results in QALY gains 33 ranging from 45,492 (95% UI, 10,281–106,579) to 157,628 (95% UI, 46,701–320,622), and 34 35 healthcare costs savings ranging from CAD\$ 695 (95% UI, 160–1,580) to CAD\$ 2,415 (95% UI, 722–4,746) million over the lifetime of the 2019 Canadian cohort. Greater health and healthcare 36

costs gains were estimated if Canadians were to meet the population-level sodium intake

- recommendations of the World Health Organization (2,000 mg/day) and the Adequate Intake
- recommendation (1,500 mg/day). All sodium reduction strategies tested were cost saving.

Conclusions

- 41 Reducing population-level sodium intakes is feasible and has the potential to improve health
- 42 outcomes and save healthcare costs in Canada. From interventions tested, most health and
- 43 healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights
- 44 the importance of changing the voluntary nature of these targets to mandatory. A combination of
- 45 strategies, mandatory sodium reduction targets and implementation of the 'high in' FOPL
- symbol would provide the most benefit from a public health standpoint.

1. Introduction

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Diets high in sodium are the main dietary risk factor for non-communicable diseases (NCDs)(1) due to their impact on cardiovascular diseases (CVDs)(2, 3), the leading cause of death globally and a major contributor to disability, particularly in relation to diseases such as ischemic heart disease (IHD) and stroke(4). In Canada, CVDs (mostly IHD and strokes) rank as the second leading cause of death (after cancers), accounting for 25% of all deaths each year(5). The World Health Organization (WHO) broadly considers reducing population-level dietary sodium intake to be a cost-effective measure that could save many lives by decreasing and preventing the burden of diet-related NCDs, mainly from CVDs, and save costs in the long run(6, 7). The WHO recommends consuming less than 2,000 mg/day of sodium (5 g/day of salt)(8); however, intake levels around the world largely exceed recommendations(8). Canada is not an exception, as recent sodium intake estimations showed that Canadians consume an average of 2,760 mg/day of sodium(9, 10), with 63.9% of Canadian adults exceeding the recommendation for Chronic Disease Risk Reduction (CDRR) levels (2,300 mg/day) and only 9.4% of Canadian adults meeting the Adequate Intake (AI) levels (1,500 mg/day)¹⁰. Reducing sodium intake is a WHO 'best buy' recommendation for the prevention and control of NCDs(6). In its SHAKE Technical Package for Salt Reduction(11), WHO recommends ideally implementing a joint combination of measures to reduce population-level sodium intakes. These measures include monitoring salt use (e.g., intakes, salt content in foods), promote food reformulation to contain less salt by setting salt targets levels in foods, adopting interpretive front-of-pack labeling systems, and restricting marketing of foods 'high in' salt, among others(11).

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

The Canadian government has implemented and adopted several evidence-based policies to make the healthier choice easier for all Canadians, as described in the Canadian Healthy Eating Strategy (2016)(12). As part of this comprehensive strategy, Health Canada committed to ongoing collaboration with stakeholders in the food industry to reduce sodium levels in packaged foods through updating the voluntary sodium reduction targets for processed foods (2020-2025)(13). It is worth noting that progress evaluations of the previous (2012-2016) set of voluntary sodium reduction targets have only shown modest results(14), and only minor revisions have been made to the latest set of targets (2020-2025)(13). In addition, Health Canada recently approved front-of-pack labeling (FOPL) regulations that will require packaged foods that meet or exceed established thresholds for nutrients-of-concern, including sodium, to display a 'high in' FOPL nutrition symbol, to come into effect by January 2026(15). Estimating the impact of public health polices, such as the aforementioned, could be challenging or simply not feasible using traditional epidemiological research methods such as cohort studies, randomized control trials or natural experiments. Policy scenario modeling has proven to be an appropriate and strategic tool for estimating the health and economic impact of public health policies prior to actual implementation(16). Specifically, NCD policy scenario modeling allows us to predict the cumulative health outcomes of interventions over the long term and across the entire population; in addition to providing evidence on what the magnitude would be to take action or not by comparing different policy scenarios with a 'business as usual' scenario(17). A systematic review of previous policy scenario modeling studies have demonstrated the costeffectiveness of reducing dietary sodium intake(18). Studies in the Canadian context have estimated the economic and health impact of reducing sodium intake to recommended levels when compared to previous sodium intake levels (i.e., 3,800 mg/day) using data from CCHS-

Nutrition 2004(19). More recently, using data from CCHS-Nutrition 2015, we previously estimated the number of CVDs deaths that could be averted or delayed if Canadians were to reduce their sodium intake to recommended levels(10, 19), and as a result of implementing 'high in' FOPL regulations(20, 21). However, to the best of our knowledge, no study in Canada has previously estimated the health impact and healthcare cost savings from 'real world' policy scenario options to reduce population level dietary sodium intakes (i.e., food reformulation and mandatory 'high in' FOPL symbol).

In this study, we aimed to provide policymakers and stakeholders with evidence supporting policy options to reduce excess dietary sodium intakes in Canada. We estimated the number of avoidable ischemic heart disease and stroke incidence cases, and their associated healthcare cost, and Quality-Adjusted Life Year (QALY) savings resulting from 1) meeting sodium intake recommended levels, 2) meeting sodium reduction targets for packaged foods established by Health Canada, and 3) implementing 'high in' front-of-pack labeling regulations in Canada.

2. Materials and methods

We conducted a cost-utility analysis using a public healthcare system perspective. The potential health and healthcare costs impact of reducing dietary sodium intake were modelled by comparing ten counterfactual scenarios (described below in section 'Counterfactual scenarios modeled') to a 'business as usual' or 'baseline' scenario. Outcomes were modeled over the lifetime of the Canadian population alive in 2019, and a 1.5% discount rate was applied to both health gains and healthcare costs, as recommended by the Canadian Agency for Drugs and Technologies in Health (CADTH)(22).

2.1PRIMEtime model: a proportional multi-state lifetable model

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

The PRIMEtime model, an established and robust proportional multi-state lifetable model, was used in this study(23, 24). PRIMEtime is an epidemiological model tool, developed by researchers at the University of Oxford, that has been widely applied to a range of different diet and obesity policy scenarios in the UK and other countries (24-31). This model has been designed for policy scenario evaluation and can be utilized to assess future effects of policies in order to help policymakers set priorities for action. In a world of limited resources, governments are increasingly required to properly assess the cost-effectiveness of interventions to strategically allocate their resources. The PRIMEtime model is a tool for policy support and prioritization that under the same set of assumptions can help compare different policy options by assessing the cost-effectiveness of interventions. The PRIMEtime model is comprised of the following interconnected modules: a risk factor exposure module, a series of disease models, and a lifetable. Detailed methods of the model have been published elsewhere (24). Briefly, PRIMEtime uses epidemiological data collected mainly from meta-analyses of randomized control trials or prospective cohort studies to parameterize the relationships between risk factors and NCDs. This can be modeled as direct effects of risk factors or via their intermediate risk factors (i.e., blood pressure, BMI, or total cholesterol), where appropriate. The Canadian PRIMEtime Salt model includes the two main CVDs associated with high consumption of salt/sodium, IHD and stroke. These diseases are modeled in PRIMEtime in a three-state Markov model in which the population is either in a disease-free state, a diseased state, or dead. Then, the lifetable combines these simulated changes in population health and healthcare system as a result of changes in disease epidemiology.

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

We adapted the PRIMEtime model to the Canadian context by collecting, processing, and analyzing Canadian-specific and nationally representative data (i.e., dietary sodium intakes, population demographics, disease epidemiology and healthcare costs). **Table 1** shows the data sources used as inputs for the PRIMEtime model in Canada. A closed cohort analyses was performed, taking the Canadian adult population as a baseline (≥19 y) over the lifetime of the cohort or until they reach 100y of age. 2.2Model input parameters Population inputs Canadian population size and all-cause mortality data by 1-year age/sex groups were included in the model. Data was obtained from the publicly available Statistics Canada CANSIM tables for the year 2019 (Table 1, Supplementary Table S1). All-cause mortality data was only available in 5-year age/sex groups; thus, further processing was required. Data was interpolated to 1-year using a temporal disaggregation method(32). Disease epidemiology Data on incidence, prevalence and disease-specific mortality were collected for ischemic heart disease and stroke for the year 2019 (Table 1). First, we prioritized alignment of WHO International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) codes(33) between disease epidemiology and healthcare cost data (described below). Disease epidemiology data was only available in 5y age/sex groups up to age 90+ for all parameters; thus, further processing was required. Data was extrapolated to age 100+ using a polynomial trend line (Supplementary Table S2). Then, health data estimates were interpolated

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

to 1y age/sex groups using a temporal disaggregation method to obtain smooth disaggregated counts, while maintaining the aggregated total(32). Case fatality rates were derived from cause-specific incidence, prevalence and mortality data, together with population size using a Bayesian approach, the disbayes optimization method built on the Stan software (disbayes package available in R)(32, 34). It was assumed that case fatality was constant for all ages below 35. The disbayes package estimates case fatality using a threestate transition process of disease free, disease, or death. The disbayes' approach and assumptions are consistent with the ones underpinning disease simulation in the PRIMEtime model (Supplementary Table S1). Mean systolic blood pressure (SBP) estimates for the year 2019 were acquired. Data was available by sex (male, female) and age group (6-11 years, 12-19, 20-39, 40-59, 60-79) (**Table** 1). As SBP measurements were not available for individuals aged 80 years and older, we assumed the same values as those observed for 60-79 years age/sex groups for individuals in the 80+ years group. Dietary sodium intake This study used data from the Canadian Community Health Survey (CCHS)-Nutrition 2015 to estimate baseline and counterfactual dietary sodium intakes for Canadian adults (≥19 y). CCHS-Nutrition 2015 is a nationally representative, cross-sectional health and nutrition survey that utilized 24-hour (24h) dietary recalls to collect data on food and beverage intake across the 10 Provinces of Canada (aged 1y or older)(35). We used both available days of 24h dietary recalls to estimate usual dietary sodium intakes for adults by Dietary Reference Intakes (DRI)(36)

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

age/sex groups (i.e., males and females ages 19-30, 31-50, 51-70, 71+), methods that have been previously published by our research group(10, 20, 21). Counterfactual scenarios modeled *Meeting sodium intake recommended levels (Scenarios 1 and 2)* We modeled potential health and healthcare costs gains from meeting WHO sodium intake recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The proportion needed to meet these recommendations from the current sodium intakes (2,758 mg/day) was calculated and applied to each DRI age/sex group to build our counterfactual scenarios¹⁰ (**Table 2, Supplementary Table S3**). *Meeting sodium reduction targets established by Health Canada (Scenario 3)* Fully meeting Health Canada's voluntary sodium reduction targets for packaged foods was used as one of the counterfactual scenarios tested in this study. Our research group has previously published methods for this policy modeling approach(10, 37). Briefly, data from a Canadian branded packaged food composition database, the University of Toronto's Food Label Information and Price database (FLIP 2017), was linked to the Food and Ingredient Details (FID) file in the CCHS-Nutrition 24-hour recall to estimate baseline and counterfactual dietary sodium intakes. The counterfactual scenario was estimated after conducting a systematic 'reformulation' of eligible packaged foods to meet Health Canada's sodium reduction targets ¹⁰ (**Table 2**, Supplementary Table S3). *Implementing 'high in' front-of-pack labeling regulations (Scenarios 4-10)*

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Based on recent FOPL evidence from observational and experimental studies (38-40), we estimated potential changes to dietary sodium intakes(20). These studies estimated changes in the content of nutrients of public health concern (i.e., saturated fats, sodium, and sugars) in food and beverage purchases when a 'high in' FOPL was in place. We assumed that changes observed in food and beverage purchases would carry over to dietary intakes, as evidence suggests that documented food purchases can serve as a reasonably precise estimate of overall diet quality(41). We modeled changes in overall food and beverage sodium content based on early evaluations of the Chilean Food Labeling and Marketing Law (-4.7%)(38) (Scenario 4), the criteria used by WHO to estimate FOPL cost-effectiveness as part of the Technical briefing for Appendix 3 of the Global Action Plan for NCDs (-6.4%)(40) (Scenario 5), and a FOPL systematic review and network meta-analysis (-7.8%)(39) (Scenario 6), (Table 2, Supplementary Table S3). Furthermore, we constructed counterfactual scenarios using data from consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We first identified foods and beverages in FLIP 2017 similar to those reported in CCHS-Nutrition 2015 that would display at least one fewer 'high in' FOPL symbol for nutrients of concern, including sodium. Then, to estimate 'new' dietary intakes, we replaced nutritional values of identified foods for a random sample of 30%, 50%, and 70% of CCHS-Nutrition adult participants that consume at least one food that would display a 'high in' symbol (Scenarios 7-9). Additionally, to estimate the potential maximum effect of FOPL, we simulated changes for all adult participants (Scenario 10) (Table 2, Supplementary Table S3). All FOPL counterfactual scenarios tested in this study are based on 'high in' FOPL evidence, which is the FOPL system recently approved in Canada. We have previously published methods

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

for all FOPL policy scenarios (20, 21). For this study, we used potential impacts of implementing FOPL only for changes in sodium intakes. Direct healthcare costs This study followed the perspective of the public healthcare system. The model estimated direct healthcare cost differences between the baseline and the modeled intervention. We used data from the 2010 Economic Burden of Illness in Canada (EBIC)(48), the most recent available and comprehensive national disease-specific costs study. Direct healthcare costs in EBIC 2010 are reported by diagnostic category disaggregated by age/sex groups. We followed previous published methods for the estimation of direct healthcare costs for each of the modeled diseases (49) (i.e., total and by prevalence case). We prioritized alignment of WHO ICD-10(33) codes between prevalence case data with EBIC 2010 categories, as well as disease definition as closely as possible with the Global Burden of Disease study (2019)(50). Therefore, we first identified the best fitting EBIC diagnostic category by matching ICD-10 codes for each disease under study. We used the EBIC 2010 online tool to produce costs for each EBIC category by sex (male, female) and age group (0-14 years, 15-34, 35-54, 55-64, 65-74, 75+)(51). Direct healthcare costs are comprised of attributable (drug, hospital care – day surgery, hospital care – inpatient, hospital care – other ambulatory care, hospital care – outpatient – clinic, hospital care – outpatient – emergency, and physician care) and unattributable direct costs (other institutions, other professionals, capital, public health, administration, and other health spending). EBIC diagnostic categories only provide disease-specific estimates for attributable direct costs, but also report total unattributable direct costs; thus, unattributable direct costs were estimated

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

and added to cost estimates per disease. The proportion of each modeled disease's share to the total attributable direct cost was estimated for each age/sex group using a method developed by Krueger et al(52). Subsequently, this proportion was applied to the total unattributable direct costs to then include these estimates in the total direct healthcare costs for each disease. Costs per disease case were then calculated by dividing estimated direct healthcare costs for each age/sex group by prevalent cases in 2010, yielding the cost per case per year. A decision was made on using prevalent cases for each disease based on their clinical pattern of exerting costs; hence, these were treated as prevalent cases. Lastly, healthcare costs were inflated to 2019 Canadian Dollars (CAD), and inflation factor was estimated using the 'health care' sub-index from the Statistics Canada Consumer Price Index(53). Methods, sources, and direct healthcare costs estimations, by each modeled disease, are described in **Table 1** and **Supplementary** Tables S4 and S5. 2.3Sensitivity analysis Sensitivity analysis was conducted to examine the impact of uncertainty in the discount rate by applying 0% and 3% discount rate, as recommended by the CADTH(22). Additionally, we also used time horizons of 10 and 50 years. 2.4Statistical analysis The National Cancer Institute (NCI) method(54) was used to estimate Canadian adults' usual sodium intakes and distributions for all adults and by DRI age/sex group (baseline and counterfactual scenarios). The 1-part (amount only) model was used as zero consumption of sodium was <5%, as recommended by Davis et al(55), which also allowed us to stratify analysis by DRI age/sex groups and to remove outliers for implausible sodium intakes. Confidence intervals and standard error were estimated using the bootstrap balanced repeated replication method (500 replicates). Additionally, we applied sample survey weights (Statistics Canada) to all analyses to ensure nationally representative estimates(35). Statistical analyses were conducted using SAS version 9.4.

After inputting all the required data in PRIMEtime, the model estimated the avoidable ischemic heart disease and stroke incidence cases, healthcare costs savings, and QALYs for each counterfactual scenario, by sex and each disease of interest. Uncertainty intervals (95% UI) were produced using Monte Carlo simulation at 5000 iterations to allow the epidemiological parameters in PRIMEtime to fluctuate randomly following the distributions considered in the model(24).

3. Results

Meeting sodium intake recommendations

Fully meeting Health Canada's sodium reduction targets was estimated to reduce mean sodium intakes to the national sodium intake recommendations (~2,300 mg/day; 17% reduction from current levels). This reduction in sodium intake was estimated to prevent 219,490 (95% UI, 73,409 – 408,630) incident cases of IHD, and 164,435 (95% UI, 56,121 – 305,770) strokes. Approximately, 63% of prevented IHD cases were estimated in males (137,188 [95% UI, 44,185 – 259,658]) and 37% in females (82,303 [95% UI, 29,224 – 148,972]), and 57% of prevented strokes were estimated in males (94,522 [95% UI, 31,032 – 179,060]) and 43% in females (69,913 [95% UI, 25,088 – 126,710]). These health gains result in an overall gain of 276,185

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

OALYs (95% UI, 85,414 – 552,616), with 62% attributed to males and 38% to females. This translates into CAD\$ 4,212 million (95% UI, CAD\$ 1,303 – CAD\$ 8,206) in healthcare cost savings (69% in males, 31% in females) over the lifetime of the 2019 Canadian cohort (**Tables 3** and 4, Figure 1 and 2). Greater health and healthcare cost gains were estimated if Canadians were to meet WHO's population-level sodium intake recommendations (2,000 mg/day) and the Adequate Intake recommendation (1,500 mg/day) (**Tables 3 and 4, Figure 1 and 2**). Implementing 'high in' front-of-pack labeling regulations Sodium intake reduction through the implementation of FOPL regulations, as suggested by early evaluations of the Chilean FOPL regulations, has the potential to prevent 57,023 (95% UI, 17,350 – 114,447) incident cases of IHD, and 41,794 (95% UI, 12,389 – 85,302) strokes. Approximately 64% of prevented IHD cases were estimated in males (36,323 [95% UI, 10,526 – 73,593]) and 36% in females (20,701 [95% UI, 6,824 – 40,854]), and 58% of prevented strokes were estimated in males (24,443 [95% UI, 7,028 – 50,943]) and 42% in females (17,351 [95% UI, 5,361 – 34,359]). These health gains result in an overall gain of 74,499 QALYs (95% UI, 21,108 – 160,246), with 63% attributed to males and 37% to females. This translates into CAD\$ 1.149 million (95% UI, CAD\$ 329 – CAD\$ 2.381) in healthcare cost savings (71% in males. 29% in females) over the lifetime of the 2019 Canadian cohort (Tables 3 and 4, Figure 1 and 2). Greater health and healthcare cost gains were projected based on the criteria used by WHO to estimate FOPL cost-effectiveness and results from a FOPL systematic review and network meta-

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

analysis. An increase of 34% and 64% in all outcomes was estimated, respectively, versus the results based on evaluations of the Chilean FOPL (Tables 3 and 4, Figure 1 and 2). Sodium intake reduction through consumer food substitution – specifically, when consumers choose food products with fewer 'high in' FOPL symbols – has the potential to prevent between 35,930 (95% UI, 8,085 – 80,528) and 124,744 (95% UI, 40,125 – 235,643) cases of IHD, and between 26,869 (95% UI, 5,235 – 61,621) and 93,129 (95% UI, 30,296 – 176,014) strokes. This results in QALY gains ranging from 45,492 (95% UI, 10,281 – 106,579) to 157,628 (95% UI, 46,701 – 320,622), and healthcare cost savings ranging from CAD\$ 695 million (95% UI, CAD\$ 160 – CAD\$ 1,580) to CAD\$ 2,415 million (95% UI, CAD\$ 722 – CAD\$ 4,746) over the lifetime of the 2019 Canadian cohort (Tables 3 and 4, Figure 1 and 2). All sodium reduction strategies tested in this study were cost saving from the public healthcare system perspective. Estimated benefits were greater for males than females in all scenarios tested. Sensitivity analysis We examined the impact of uncertainty in the discount rate by applying discount rates of 3% and 0%. When a 3% discount rate was applied to both health and healthcare cost outcomes, a decrease of 44% and 39% were observed on average for QALYs and healthcare costs, respectively, in all scenarios. Conversely, when a 0% discount rate was applied, an increase of 96% and 78% were observed on average for QALYs and healthcare costs, respectively, in all scenarios (See Supplementary Table S10).

Furthermore, using time horizons of 10 and 50 years, the model predicted that 7% and 76%, respectively, of estimated lifetime healthcare cost savings would occur within those time horizons. For QALYs gained, the model estimated that 4% and 67%, respectively, of estimated lifetime gains would occur within those same time horizons (See **Supplementary Table S11**).

4. Discussion

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

This study estimated the potential impact of reducing sodium intake on the incidence of ischemic heart disease and stroke cases, savings in healthcare costs, and QALYs gains. Our results demonstrate that reducing sodium intakes through population-level strategies, such as implementing sodium reduction targets and 'high in' FOPL regulations, has the potential to improve health outcomes and reduce healthcare expenditures in Canada. This adds to current evidence, generated by simulation modeling studies, showing that sodium reduction strategies can potentially improve health outcomes and save costs to the health system, globally (29, 56-62) and in Canada(10, 19). To the best of our knowledge, this is the first study estimating the potential health (QALYs) and healthcare costs of current sodium reduction initiatives in Canada. We tested ten counterfactual scenarios aiming to reduce population sodium intake. These included achieving recommended sodium intakes levels (2,000 and 1,500 mg/day); meeting sodium reduction targets for packaged foods established by Health Canada (food reformulation, 2,300 mg/day); and estimated changes in sodium intake resulting from implementing the recently approved 'high in' FOPL regulations. As expected, our results showed the greatest health gains and healthcare cost savings from meeting population-level sodium intake recommendations of 2,000 mg/day (441,475 QALYs; CAD\$ 6,692 million in healthcare costs savings) and 1,500 mg/day (701,592 QALYs; CAD\$

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

10,624 million in healthcare costs savings). Our study sheds light on how far Canadians are from achieving these maximum benefits with current sodium reduction policy initiatives. For instance, for the policy initiatives tested in this study (i.e., meeting sodium reduction targets and implementing 'high in' FOPL regulations), most health and healthcare costs gains were attributed to fully meeting Health Canada's sodium reduction targets (276,185 QALYs; CAD\$ 4,212 million in healthcare costs savings). Greater benefits were observed for males than females, in all scenarios tested, which could be attributed to differences in sodium consumption and CVD burden among Canadians males and females (9, 10, 63). Unfortunately, progress evaluations have shown that compliance with the voluntary sodium reduction targets has been limited, with only 14% of food categories meeting the targets by 2017(14), indicating that to meet targets by 2025(13) faster progress is needed. A robust government-led monitoring system and higher compliance from the food industry could contribute towards increasing sodium reduction progress in Canada. The consequences of not meeting established sodium reduction targets for processed foods represents an important missed opportunity to generate substantial health and healthcare costs gains in Canada. Canada could benefit from other countries experiences that have implemented mandatory sodium reduction targets. For instance, South Africa's legislation setting mandatory maximum sodium levels in foods has led to a decrease of 1.15 g/day in salt intake (~460 mg/day of sodium) in a four-year period (2015-2019). Interestingly, similar sodium reduction levels were estimated for our scenario of fully meeting sodium reduction targets (64), which indicates the feasibility of this strategy. This also highlights the importance of changing the voluntary nature of sodium reduction targets in Canada to mandatory sodium reduction targets. More recently, the WHO released the WHO global sodium benchmarks for different food categories (65). This set of

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

sodium reduction targets includes 18 main food categories and 97 food subcategories. Greater benefits would be expected from meeting these targets in Canada, given that for several common food categories WHO targets are more stringent than Health Canada's sodium reduction targets. In Australia, it has been estimated that meeting WHO benchmarks, as opposed to meeting Australian sodium reduction targets, could prevent or delay nearly three and a half times as many diet related NCD deaths(62). The potential impact of FOPL regulations was estimated through two pathways. The first was based on recent FOPL evidence from observational and experimental studies (38-40) that estimated changes in the content of nutrients of public health concern, including sodium, in food and beverage purchases when a 'high in' FOPL was in place. Among these scenarios is one based on early evaluations of the Chilean FOPL (S4), which most likely captured consumer behavior change and initial industry-driven food reformulation. The health and healthcare cost gains estimated from this scenario represent approximately 27% of the gains estimated from meeting Health Canada's sodium reduction targets. The second pathway was based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47), which would only capture consumer behavior change. The estimated benefits from these scenarios range from 16% to 57% of the benefits estimated from meeting Health Canada's sodium reduction targets. The differences in FOPL scenarios tested are reflected in our estimates. We observed greater benefits from changes observed in food and beverage purchases in the presence of FOPL (S4-6) than from food substitution as a response of FOPL (S7-9). It is worth noting that our study focused solely on benefits from reducing sodium intake as a result of implementing FOPL in Canada. Therefore, it is expected that implementation of FOPL will result in greater health and

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

healthcare cost benefits, as it also targets other nutrients-of-concern (i.e., sugars and saturated fats) not accounted for in our estimates. For instance, a recent study from our research group estimated that 15% of diet related NCD deaths that could be averted or delayed due to implementation of FOPL in Canada were attributed to sodium(21). A previous Canadian modeling study estimated potential heath and healthcare cost benefits, over a 50-year time horizon, from reducing sodium intake levels by 1,500 mg/day(19). They estimated benefits of 1,021,458 QALYs and CAD\$16,805 million in healthcare cost savings(19). In comparison, the largest reduction we tested was a reduction in sodium intake of 1,258 mg/day to achieve the AI recommendations (1,500 mg/day). Under this scenario we projected benefits of 471,748 QALYs and CAD\$ 8,083 million in healthcare cost savings over a 50-year time horizon. Differences likely stem from variations in the magnitude of the tested sodium reduction intake (reductions of 1500 mg/day vs. 1,258 mg/day), differences in methodology used to estimate healthcare costs, improved management of SBP in Canada, and slight reductions observed in the burden of CVDs in Canada. In the US a sodium reduction of 1,200 mg/day has been predicted to gain between 194,000 and 392,000 QALYs and save between \$10,000 to \$24,000 million in healthcare costs(66). This study has limitations and strengths that need to be considered in the interpretation of our results. First, scenario modeling is an analytical technique; hence, results are as appropriate and generalizable as the data, assumptions and constraints that are applied to the mathematical model(67). To mitigate this, we used Canadian–specific and nationally representative data as inputs for the model. Additionally, our counterfactual sodium reduction intervention scenarios are based on Canadian sodium reduction targets and the most recent available evidence on the impact of FOPL regulations. We followed the perspective of the public healthcare system; hence,

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

the costs of implementing the sodium reduction interventions were not considered. Although population-wide sodium reduction interventions in Canada were estimated to cost CAD\$2.02 per person annually (Canadian population in 2019: 38 million approximately), these costs would be minimal in comparison with savings in healthcare costs(19, 68). These costs included government led industry agreements to reduce sodium in packaged foods, government monitoring of industry compliance, and public health campaigns (19, 68). We also did not consider societal gains in our modeling, such as productivity gains from preventing premature deaths or disease burden. Furthermore, we focused on the potential health effects of reducing sodium intake, specifically health effects from IHD and stroke, the leading causes of death globally. However, recent studies have estimated potential effects of reducing sodium on other diseases such as chronic kidney disease and stomach cancer (58, 59, 69, 70). Therefore, our estimations of the potential benefits of reducing population-level sodium intake are conservative, considering that reducing sodium intake could also have positive effects on other diseases. Lastly, this study used data for the entire Canadian population without considering equity aspects. Future research can expand our work by examining the differential impacts of reducing sodium intake among diverse subgroups. This study also has strengths to consider. Dietary sodium intake data was estimated using data from a nationally representative sample of the Canadian population (CCHS-Nutrition 2015). Surveys of this kind are usually prone to biases related to misreporting due to recall bias. Nevertheless, CCHS-Nutrition 2015 used the Automated Multiple Pass Method to reduce the impact of such reporting errors. We used the NCI method to estimate usual sodium intakes and adjusted for age, sex, dietary misreporting status, weekend/weekday, and sequence of dietary recall. For modeling we used the PRIMEtime model, a robust, validated and widely used

proportional multi-state lifetable model (23, 24). Strengths and limitations of the model have been previously published(24). We also conducted sensitivity analysis to examine the impact of uncertainty in the discount rate by applying 0% and 3% discount rates, as has been recommended(22). As expected, variations in discount rates, both higher and lower than our main analysis (1.5% discount rate), had a significant impact on health and healthcare cost outcomes. Our findings provide evidence for policymakers and stakeholders of the potential benefits of reducing sodium intake through strategies widely discussed in Canada that target packaged foods. This is especially relevant because packaged foods are the main source of sodium intake for Canadians(9). Multicomponent strategies have proven to be more effective and are necessary for reaching the national and global sodium recommendations (11, 71). Therefore, in addition to moving from voluntary to mandatory sodium reduction targets for packaged foods and implementing 'high in' FOPL regulations, other initiatives should be considered for Canadians to meet population-level sodium intake recommendations (2,000 and 1,500 mg/day). These could include setting sodium reduction targets for restaurant foods, restricting marketing of foods 'high in' sodium, enabling healthy food environments in public settings by providing lower sodium options, regulating the digital food environment to require nutritional information, encouraging the use of low-sodium, potassium-enriched salt, and adopting approaches such as social marketing to develop behavior change communication and mass media campaigns(11, 72, 73). A combination of strategies, as has been recommended by the WHO's SHAKE Technical Package

for Salt Reduction(11), would be of most benefit from a public health standpoint.

5. Conclusions

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

Reducing population-level sodium intakes is feasible and has the potential to improve health outcomes and save healthcare costs in Canada. From the interventions tested most health and healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights the importance of changing the voluntary nature of these targets to mandatory. A combination of strategies, mandatory sodium reduction targets and implementation of the 'high in' FOPL symbol would be of most benefit from a public health standpoint. Thus, policymakers and stakeholders need to strengthen, and coordinate actions aimed at reducing sodium levels in the Canadian food supply. This is crucial for improving health outcomes and saving healthcare costs. Future studies could leverage this work to evaluate potential variations in effects among diverse subgroups in Canada.

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. **Authors' contributions** NF, AJ, and MRL conceptualized the study design; NF, AJ, BAC, LC, EN and MRL interpreted the findings; NF conducted the study, wrote the original draft, and performed the statistical analysis. All authors critically reviewed and approved the final manuscript. **Funding** This research was funded by Canadian Institutes of Health Research (CIHR) operating grants (PJT-165858; SA2-152805; Healthy Cities Training Award). https://cihr-irsc.gc.ca/e/193.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgments The authors would like to thank Professor Peter Scarborough, University of Oxford, for allowing us to use the PRIMEtime model and discussing its application; as well as current and past L'Abbe lab members who worked on various aspects of the FLIP database, especially Anthea Christoforou who worked and published data on the sodium reformulation scenario used in this manuscript. Furthermore, the authors would like to acknowledge the assistance of Arantxa Bonifaz Rosas with the collection of Canadian healthcare cost data.

Analytic code (R) can be made available to researchers upon request to the author. Canadian

Community Health Survey-Nutrition 2015 Public Use Microdata File (PUMF) data is publicly
and freely available without restriction at Statistics Canada,

https://www150.statcan.gc.ca/n1/en/catalogue/82M0024X

Canadian population demographics, healthcare costs and epidemiology data associated with
ischemic heart disease and stroke were obtained from publicly available sources — also detailed
in the main manuscript.

https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501

https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310070901

https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310014701

https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310014701

https://health-infobase.canada.ca/ccdss/data-tool/

https://cost-illness.canada.ca/custom-personnalise/national.php

Table 1. Key data sources used for the application of the PRIMEtime Salt model in Canada

Parameter	Data source	Details	Year 2019	
Canadian population demographics	Statistics Canada: Table 17-10-0005-01 (Formerly CANSIM 051-0001)	1y age/sex groups 0–100+ years		
Deaths	Statistics Canada: Table: 13-10-0709-01 (Formerly CANSIM 102-0503)	5y age/sex groups 0–100+ years	2019	
Disease-specific deaths	Statistics Canada: Table: 13-10-0147-01 5y age/sex groups (Formerly CANSIM 102-0529) 0–90+ years		2019	
Disease-specific prevalence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years		
Disease-specific incidence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019	
Case fatalities	Were derived from Statistics Canada estimates of incidence, prevalence, and deaths, using the <i>disbayes</i> R package.	1y age/sex groups 0–100+ years	2019	
SBP estimates	Statistics Canada: Table: 13-10-0326-01 (Formerly CANSIM 117-0008)	different age/sex groups 6-79 years	2019	
Sodium intake	Canadian Community Health Survey- Nutrition 2015	DRI age/sex groups 19+ years	2015	
Direct healthcare costs, disease-specific	Economic Burden of Illness in Canada	different age/sex groups 0–75+ years	2010	
Consumer price index	Statistics Canada: Table 18-10-0005-01 (Formerly CANSIM 326-0021)	1 health care sub-index		
Utility weights	Parameters used to estimate disease-specific and background utility weights were extracted from a UK catalogue of EQ-5D scores disease-specific prevalence and incidence weights; and by 10y age bands		2011	
Relative risks	risks Disease associated relative risks were derived from a systematic review and meta-analysis (Per 20 mmHg of SBP) evidence from prospective studies; different age/sex groups <49-79+ years		2002	

505 SBP, systolic blood pressure.

Table 2. Sodium reduction counterfactual scenarios 506 507


Counterfactual scenarios		Based on	Parameters modeled	Δ Sodium*	Δ Salt*
Meeting sodium intake recommendations	S1: AI sodium intake recommendations (1,500 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 1,258 mg/day	- 3.14 g/day
	S2: WHO sodium intake recommendations (2,000 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 758 mg/day	- 1.89 g/day
	S3: Sodium reduction targets for packaged foods, reformulation (2,300 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Food & beverages with a sodium target	- 459 mg/day	- 1.15 g/day
Implementing 'high in' FOPL regulations (food and	S4: Changes in food & beverage purchases (Chilean FOPL experience) (20)	Taillie L, et al (2021) (38)	Changes in sodium content of food & beverage purchases	- 128 mg/day	- 0.32 g/day
beverage purchases)	S5: Based on WHO criteria to estimate cost- effectiveness of FOPL policies (20)	WHO (2022) (40)	Changes in sodium content of food & beverage purchases	- 174 mg/day	- 0.44 g/day
	S6: Based on a FOPL systematic review and network meta-analysis (20)	Song J, et al (2021) (39)	Changes in sodium content of food & beverage purchases	- 212 mg/day	- 0.53 g/day
Implementing 'high in' FOPL regulations (food	S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 73 mg/day	- 0.18 g/day
substitution)	S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 131 mg/day	- 0.33 g/day
	S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 182 mg/day	- 0.45 g/day
	S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 259 mg/day	- 0.65 g/day

*These values are overall intervention effect. Intervention effect by DRI age/sex group, as imputed in the PRIMEtime model, are detailed in Supplementary Table 508 509 S3. Full details of each counterfactual scenario have been published elsewhere (10, 20, 21). We considered the potential impacts of FOPL implementation solely


510 for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; mg, milligram; CCHS, Canadian

511 Community Health Survey.

Figure 1. Estimated QALY gained over the lifetime of the 2019 cohort, by sex and sodium reduction strategy



The potential QALYs gained were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on WHO sodium intake recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The sodium target scenario was based on fully meeting Health Canada's voluntary sodium reduction targets for packaged foods. The FOPL—changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL—food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.



The potential healthcare cost savings were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day and the WHO sodium intake recommendations of 2,000 mg/day. The sodium target scenario was based on fully meeting Health Canada's voluntary sodium reduction targets for packaged foods. The FOPL—changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL—food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

Table 3. Prevented disease incident cases over the lifetime of the cohort, by sex and sodium

reduction strategy

532

Count	erfactual scenarios	IHD incidence cases	%	Stroke incidence cases	%
ions	S1: Meeting AI sodium intake recommendations (1,500 mg/day)	558,395 (191,157 – 1,032,085)	100%	418,281 (147,760 – 762,689)	100%
ımendat	Males (95% UI)	344,273 (111,585 – 647,015)	62%	236,728 (79,646 – 439,265)	57%
	Females (95% UI)	214,123 (79,572 – 385,070)	38%	181,553 (68,114 – 323,425)	43%
scon	S2: Meeting WHO sodium intake recommendations				
Ke re	(2,000 mg/day)	350,142 (117,927 – 649,693)	100%	261,877 (88,387 – 481,374)	100%
intal	Males (95% UI)	217,586 (70,367 – 410,138)	62%	149,596 (48,512 – 278,702)	57%
m m	Females (95% UI)	132,556 (47,561 – 239,555)	38%	112,280 (39,875 – 202,672)	43%
Meeting sodium intake recommendations	S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)	219,490 (73,409 – 408,630)	100%	164,435 (56,121 – 305,770)	100%
l eet	Males (95% UI)	137,188 (44,185 – 259,658)	63%	94,522 (31,032 – 179,060)	57%
_	Females (95% UI)	82,303 (29,224 – 148,972)	37%	69,913 (25,088 – 126,710)	43%
'erage	S4: Changes in food & beverage purchases (Chilean experience)	57,023 (17,350 – 114,447)	100%	41,794 (12,389 – 85,302)	100%
bev	Males (95% UI)	36,323 (10,526 – 73,593)	64%	24,443 (7,028 – 50,943)	58%
and	Females (95% UI)	20,701 (6,824 – 40,854)	36%	17,351 (5,361 – 34,359)	42%
changes in food and beverage purchases	S5: Based on WHO criteria to estimate cost- effectiveness of FOPL policies	76,555 (24,471 – 150,693)	100%	56,322 (18,202 – 111,634)	100%
ges	Males (95% UI)	48,704 (14,968 – 96,967)	64%	32,914 (10,308 – 65,871)	58%
chan	Females (95% UI)	27,851 (9,503 – 53,726)	36%	23,409 (7,894 – 45,763)	42%
FOPL – (S6: Based on a FOPL systematic review and network meta-analysis	93,714 (31,069 – 181,713)	100%	69,000 (23,030 – 135,388)	100%
)Ľ	Males (95% UI)	59,803 (19,070 – 117,662)	64%	40,490 (13,046 – 80,568)	59%
	Females (95% UI)	33,911 (11,999 – 64,051)	36%	28,511 (9,985 – 54,820)	41%
	S7: Based on food substitution for 30% of CCHS- Nutrition 2015 adult participants	35,930 (8,058 – 80,528)	100%	26,869 (5,235 – 61,621)	100%
	Males (95% UI)	22,968 (5,336 – 51,212)	64%	15,860 (3,221 – 36,350)	59%
u.	Females (95% UI)	12,962 (2,722 – 29,315)	36%	11,009 (2,013 – 25,271)	41%
ituti	S8: Based on food substitution for 50% of CCHS-	(2.012.(10.000125.005)	1000/	46.060 (14.660 - 04.001)	1000/
ıbsti	Nutrition 2015 adult participants	63,013 (19,800 – 127,007)	100%	46,868 (14,668 – 94,881)	100%
ıs po	Males (95% UI) Females (95% UI)	40,472 (12,467 – 82,378) 22,541 (7,332 – 44,628)	64% 36%	27,767 (8,508 – 56,851) 19,101 (6,160 – 38,030)	59% 41%
of -		22,341 (7,332 - 44,026)	30%	19,101 (0,100 – 38,030)	41 %
FOPL – food substitution	S9: Based on food substitution for 70% of CCHS- Nutrition 2015 adult participants	86,135 (28,713 – 166,394)	100%	63,961 (21,187 – 124,102)	100%
	Males (95% UI)	55,461 (17,911 – 108,730)	64%	37,984 (12,216 – 74,661)	59%
	Females (95% UI)	30,674 (10,802 – 57,664)	36%	25,977 (8,971 – 49,441)	41%
	S10: Based on food substitution for all CCHS- Nutrition 2015 adult participants	124,744 (40,125 – 235,643)	100%	93,129 (30,296 – 176,014)	100%
	Males (95% UI)	78,998 (24,224 – 151,268)	63%	54,299 (16,845 – 104,141)	58%
53/	Females (95% UI)	45,746 (15,901 – 84,375)	37%	38,830 (13,451 – 71,873)	42%

The potential health impacts were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health Canada's voluntary sodium reduction targets for packaged foods. The FOPL—changes in F&B purchase scenarios (S4-6) were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL—food substitution scenarios (S7-10) were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, ischemic heart disease; WHO, World Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey.

Table 4. Estimated health gains and healthcare cost savings over the lifetime of the cohort, by sex and sodium reduction strategy

545

Counterfactual scenarios		QALY gains	%	Healthcare cost savings (CAD\$ million)	%
su	S1: Meeting AI sodium intake recommendations (1,500 mg/day)	T01 502 (225 (T0 1 202 220)	1000/	10 (24 (2.25) 20 (75)	1000/
Meeting sodium intake recommendations	•	701,592 (225,679 – 1,393,230)	100%	10,624 (3,356 – 20,665)	100%
	Males (95% UI)	425,297 (126,968 – 860,372)	61%	7,295 (2,183 – 14,410)	69%
	Females (95% UI)	276,295 (98,711 – 532,858)	39%	3,329 (1,173 – 6,255)	31%
e recc	S2: Meeting WHO sodium intake recommendations (2,000 mg/day)	441,475 (135,508 – 891,597)	100%	6,692 (2,092 – 13,017)	100%
ntak	Males (95% UI)	269,816 (77,889 – 555,809)	61%	4,626 (1,383 – 9,108)	69%
im i	Females (95% UI)	171,659 (57,619 – 335,788)	39%	2,067 (708 – 3,909)	31%
g sodii	S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)	277 107 (07 414 572 747)	1000/	4.212 (4.202 - 9.204)	1000/
etin	., .	276,185 (85,414 – 552,616)	100%	4,212 (1,303 – 8,206)	100%
Ĭ	Males (95% UI)	169,889 (50,166 – 344,868) 106,296 (35,248 – 207,748)	62%	2,926 (868 – 5,769)	69%
	Females (95% UI)	106,296 (35,248 – 207,748)	38%	1,286 (435 – 2,437)	31%
rage	S4: Changes in food & beverage purchases (Chilean experience)	74,499 (21,108 – 160,246)	100%	1,149 (329 – 2,381)	100%
beve	Males (95% UI)	46,889 (12,607 – 102,243)	63%	814 (220 – 1,708)	71%
and l	Females (95% UI)	27,609 (8,501 – 58,003)	37%	336 (109 – 673)	29%
changes in food and beverage purchases	S5: Based on WHO criteria to estimate cost- effectiveness of FOPL policies	99,867 (29,314 – 210,195)	100%	1,535 (455 – 3,119)	1009
	Males (95% UI)	62,782 (17,670 – 134,336)	63%	1,085 (308 – 2,231)	71%
	Females (95% UI)	37,084 (11,644 – 75,859)	37%	449 (147 – 888)	29%
1	S6: Based on a FOPL systematic review and network meta-analysis	121,817 (37,065 – 252,387)	100%	1,876 (573 – 3,802)	1009
FOPL -	Males (95% UI)	76,734 (22,375 – 161,718)	63%	1,329 (391 – 2,725)	71%
	Females (95% UI)	45,083 (14,690 – 90,669)	37%	548 (181 – 1,077)	29%
	S7: Based on food substitution for 30% of CCHS-	, , , , , ,			
	Nutrition 2015 adult participants	45,492 (10,281 – 106,579)	100%	695 (160 – 1,580)	1009
	Males (95% UI)	28,620 (6,375 – 68,250)	63%	492 (110 –1,123)	71%
u o	Females (95% UI)	16,872 (3,906 – 38,329)	37%	204 (50 – 457)	29%
stituti	S8: Based on food substitution for 50% of CCHS- Nutrition 2015 adult participants	80,321 (23,373 – 169,543)	100%	1,231 (367 – 2,549)	100%
qns	Males (95% UI)	50,867 (14,373 – 108,277)	63%	875 (254 – 1,835)	71%
FOPL – food substitution	Females (95% UI)	29,454 (9,001 – 61,265)	37%	356 (113 – 714)	29%
	S9: Based on food substitution for 70% of CCHS- Nutrition 2015 adult participants	110,063 (34,011 – 228,868)	100%	1,688 (512 – 3,427)	100%
	Males (95% UI)	69,860 (20,880 – 147,630)	63%	1,202 (351 – 2,468)	71%
	Females (95% UI)	40,203 (13,131 – 81,239)	37%	486 (161 – 959)	29%
	S10: Based on food substitution for all CCHS- Nutrition 2015 adult participants	157,628 (46,701 – 320,622)	100%	2,415 (722 – 4,746)	1009
	Males (95% UI)	98,309 (27,375 – 203,349)	62%	1,696 (482 – 3,376)	70%
	Females (95% UI)	59,318 (19,326 – 117,273)	38%	719 (239 – 1,370)	30%

The potential health gains and healthcare cost savings were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health Canada's voluntary sodium reduction targets for packaged foods. The FOPL—changes in F&B purchase scenarios (S4-6) were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL—food substitution scenarios (S7-10) were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, WHO, World Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey; QALY, Quality-Adjusted Life Year; CAD\$, Canadian dollars.

References

- 1. Institute for Health Metrics and Evaluation (IHME). GBD Compare Seattle, WA: IHME,
- University of Washington, 2019.2019 [Available from: http://vizhub.healthdata.org/gbd-
- 561 compare.

- 562 2. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global
- sodium consumption and death from cardiovascular causes. New England Journal of Medicine.
- 564 2014;371(7):624-34.
- 565 3. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C,
- et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for
- the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A
- Report of the American College of Cardiology/American Heart Association Task Force on
- Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018;71(19):e127e248.
- 571 4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.
- Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD
- 573 2019 study. Journal of the American College of Cardiology. 2020;76(25):2982-3021.
- 574 5. World Health Organization. Noncommunicable diseases country profiles 2018 2018
- 575 [Available from: https://apps.who.int/iris/handle/10665/274512.
- 576 6. World Health Organization. Tackling NCDs: 'best buys' and other recommended
- interventions for the prevention and control of noncommunicable diseases 2017 [Available from:
- 578 https://apps.who.int/iris/handle/10665/259232.
- 579 7. World Health Organization. Saving lives, spending less: a strategic response to
- 580 noncommunicable diseases Geneva, Switzerland.2018 [Available from:
- 581 https://apps.who.int/iris/handle/10665/272534.
- 582 8. World Health Organization. Salt reduction 2020 [Available from:
- 583 https://www.who.int/news-room/fact-sheets/detail/salt-reduction.
- Health Canada. Sodium Intake of Canadians in 2017 2018 [Available from:
- 585 https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-
- nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf.
- 587 10. Flexner N, Christoforou AK, Bernstein JT, Ng AP, Yang Y, Fernandes Nilson EA, et al.
- 588 Estimating Canadian sodium intakes and the health impact of meeting national and WHO
- recommended sodium intake levels: A macrosimulation modelling study. PLOS ONE.
- 590 2023;18(5):e0284733.
- 591 11. World Health Organization. The SHAKE Technical Package for Salt Reduction. Geneva:
- 592 WHO;2016. [Available from:
- 593 https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.pdf?sequence=1.
- 594 12. Health Canada. Healthy Eating Strategy 2016 [Available from:
- 595 https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-
- strategy.html.
- 597 13. Government of Canada. Voluntary sodium reduction targets for processed foods 2020-
- 598 2025 2020 [Available from: https://www.canada.ca/en/health-canada/services/food-
- 599 nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html.
- 600 14. Health Canada. Sodium Reduction in Processed Foods in Canada: An Evaluation of
- Progress toward Voluntary Targets from 2012 to 2016 2018 [Available from:
- 602 https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-

- 603 <u>guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods-</u> 604 <u>progress-report-2017/pub1-eng.pdf.</u>
- 605 15. Government of Canada. Regulations Amending the Food and Drug Regulations (Nutrition
- 606 Symbols, Other Labelling Provisions, Vitamin D and Hydrogenated Fats or Oils): SOR/2022-
- 608 dors168-eng.html.
- 609 16. Scarborough P, Harrington RA, Mizdrak A, Zhou LM, Doherty A. The preventable risk
- integrated ModEl and its use to estimate the health impact of public health policy scenarios.
- 611 Scientifica. 2014;2014.
- 612 17. Webber L, Mytton OT, Briggs AD, Woodcock J, Scarborough P, McPherson K, et al.
- The Brighton declaration: the value of non-communicable disease modelling in population health
- sciences. European journal of epidemiology. 2014;29:867-70.
- 615 18. Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of
- economic evaluations of population-based sodium reduction interventions. PLoS One.
- 617 2017;12(3):e0173600.
- 618 19. Qureshi H. The Economic Impact of Dietary Sodium Reduction in Canada. Calgary,
- 619 Canada: University of Calgary; 2017.
- 620 20. Flexner N, Ng AP, Ahmed M, Khandpur N, Acton RB, Lee JJ, et al. Estimating the
- dietary and health impact of implementing front-of-pack nutrition labeling in Canada: A
- macrosimulation modeling study. Frontiers in Nutrition. 2023;10.
- 623 21. Flexner N, Ahmed M, Mulligan C, Bernstein JT, Christoforou AK, Lee JJ, et al. The
- estimated dietary and health impact of implementing the recently approved 'high in' front-of-
- package nutrition symbol in Canada: a food substitution scenario modeling study. Frontiers in
- 626 Nutrition. 2023;10.
- 627 22. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the
- 628 economic evaluation of health technologies: Canada. Ottawa: CADTH; 2017 Mar.
- 629 23. Dötsch-Klerk M, Bruins MJ, Detzel P, Martikainen J, Nergiz-Unal R, Roodenburg AJ, et
- al. Modelling health and economic impact of nutrition interventions: a systematic review.
- European Journal of Clinical Nutrition. 2022:1-14.
- 632 24. Cobiac LJ, Law C, Scarborough P. PRIMEtime: an epidemiological model for informing
- diet and obesity policy. medRxiv. 2022:2022.05. 18.22275284.
- 634 25. Cobiac LJ, Scarborough P, Kaur A, Rayner M. The Eatwell guide: modelling the health
- implications of incorporating new sugar and fibre guidelines. PLoS One. 2016;11(12).
- 636 26. Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMEtime CE: a multistate
- 637 life table model for estimating the cost-effectiveness of interventions affecting diet and physical
- 638 activity. BMC Health Serv Res. 2019;19(1):485.
- 639 27. Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is Doctor Referral to a Low-
- 640 Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?
- 641 Obesity. 2019;27(3):391-8.
- 642 28. Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The
- potential health impact of restricting less-healthy food and beverage advertising on UK television
- between 05.30 and 21.00 hours: A modelling study. PLoS medicine. 2020;17(10):e1003212.
- Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003
- to 2018 Population Salt Intake Reduction Program in England: A Modeling Study. Hypertension.
- 647 2021;77(4):1086-94.

- 648 30. Cobiac LJ, Scarborough P. Modelling the health co-benefits of sustainable diets in the
- 649 UK, France, Finland, Italy and Sweden. European journal of clinical nutrition. 2019;73(4):624-650 33.
- 651 31. Aminde LN, Phung HN, Phung D, Cobiac LJ, Veerman JL. Dietary salt reduction,
- prevalence of hypertension and avoidable burden of stroke in Vietnam: modelling the health and
- economic impacts. Frontiers in public health. 2021;9:682975.
- 654 32. Jackson C. Bayesian estimation of chronic disease epidemiology from incomplete data:
- the disbayes package 2023 [Available from:
- 656 https://chjackson.github.io/disbayes/articles/disbayes.html#data-required-by-the-bayesian-model.
- 657 33. World Health Organization. International Statistical Classification of Diseases and
- Related Health Problems 10th Revision 2016 [Available from:
- https://icd.who.int/browse10/2016/en#/I20-I25.
- 34. Jackson C, Zapata-Diomedi B, Woodcock J. Bayesian multistate modelling of incomplete
- 661 chronic disease burden data. Journal of the Royal Statistical Society Series A: Statistics in
- 662 Society. 2023;186(1):1-19.
- 663 35. Health Canada. 2015 Canadian Community Health Survey Nutrition. Reference Guide
- to Understanding and Using the Data 2017 [Available from: https://www.canada.ca/en/health-
- $\underline{canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-surveillance/health-nutrition-su$
- community-health-survey-cchs/reference-guide-understanding-using-data-2015.html.
- 667 36. National Academies of Sciences Engineering and Medicine. Dietary Reference Intakes
- 668 Collection 2022 [Available from: https://nap.nationalacademies.org/collection/57/dietary-
- reference-intakes.
- 670 37. Bernstein JT, Christoforou AK, Flexner N, L'Abbe MR. Comparing the nutritional
- 671 composition of foods and beverages in the Canadian Nutrient File to a large representative
- database of Canadian prepackaged foods and beverages. PLOS ONE. 2023;18(3):e0280028.
- 673 38. Taillie LS, Bercholz M, Popkin B, Reyes M, Colchero MA, Corvalán C. Changes in food
- purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before
- and after study. The Lancet Planetary Health. 2021;5(8):e526-e33.
- 676 39. Song J, Brown MK, Tan M, MacGregor GA, Webster J, Campbell NR, et al. Impact of
- color-coded and warning nutrition labelling schemes: A systematic review and network meta-
- analysis. PLoS Medicine. 2021;18(10):e1003765.
- 679 40. World Health Organization. Technical briefing for Appendix 3 of the Global Action Plan
- 680 for Non-Communicable Diseases 2022 [Available from:
- 681 https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-
- 682 <u>ncd-action-plan-2013-2030</u>.
- 683 41. Appelhans BM, French SA, Tangney CC, Powell LM, Wang Y. To what extent do food
- purchases reflect shoppers' diet quality and nutrient intake? International Journal of Behavioral
- Nutrition and Physical Activity. 2017;14(1):1-10.
- 686 42. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley
- sobre composición nutricional de los alimentos y su publicidad 2017 [Available from:
- https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%c3%b3n-Ley-
- 689 20606-junio-2017-PDF.pdf.
- 690 43. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la ley sobre
- 691 composición nutricional de los alimentos y su publicidad 2018 [Available from:
- 692 https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementación-Ley-20606-
- 693 febrero-18-1.pdf.

- 694 44. Ministerio de Salud de Chile. Informe sobre evaluaciones de la Ley Nº 20.606 sobre
- composicion nutricional de los alimentos y su publicidad 2021 [Available from:
- 696 https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-oct2021.pdf.
- 698 45. Bromberg M, Sinai T, Keinan-Boker L, Endevelt R, Frankenthal D. Current use of
- 699 nutrition facts tables and attitudes towards new red and green front-of-package labels among
- Israeli consumers. International Journal of Food Sciences and Nutrition. 2022;73(2):230-7.
- 701 46. Shahrabani S. The impact of Israel's Front-of-Package labeling reform on consumers'
- behavior and intentions to change dietary habits. Israel Journal of Health Policy Research.
- 703 2021;10(1):1-11.
- 704 47. Mansfield ED, Ibanez D, Chen F, Chen E, de Grandpré E. Efficacy of "High in" Nutrient
- 705 Specific Front of Package Labels—A Retail Experiment with Canadians of Varying Health
- 706 Literacy Levels. Nutrients. 2020;12(10):3199.
- 707 48. Public Health Agency of Canada. Economic Burden of Illness in Canada, 2010 2018
- 708 [Available from: https://www.canada.ca/en/public-health/services/publications/science-research-
- 709 data/economic-burden-illness-canada-2010.html.
- Jones AC. Predicting the potential health and economic impact of a sugary drink tax in
- 711 Canada: a modelling study: UWSpace; 2018.
- 712 50. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD
- 713 2019) Data Resources 2019 [Available from: https://ghdx.healthdata.org/gbd-2019.
- 714 51. Government of Canada. Economic Burden of Illness in Canada custom report generator
- 715 2010 [Available from: https://cost-illness.canada.ca/custom-personnalise/national.php.
- 716 52. Krueger H, Krueger J, Koot J. Variation across Canada in the economic burden
- attributable to excess weight, tobacco smoking and physical inactivity. Canadian journal of
- 718 Public health. 2015;106(4):e171-e7.
- 719 53. Canada S. Consumer Price Index, annual average, not seasonally adjusted. Statistics
- 720 Canada: Table 18-10-0005-01 (formerly CANSIM 326-0021) 2019 [Available from:
- 721 https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501.
- 722 54. National Cancer Institute. Usual Dietary Intakes: SAS Macros for the NCI Method 2018
- 723 [Available from: https://epi.grants.cancer.gov/diet/usualintakes/macros.html.
- 724 55. Davis KA, Gonzalez A, Loukine L, Qiao C, Sadeghpour A, Vigneault M, et al. Early
- experience analyzing dietary intake data from the Canadian Community Health Survey—
- nutrition using the National Cancer Institute (NCI) method. Nutrients. 2019;11(8):1908.
- 727 56. Nilson EAF, Pearson-Stuttard J, Collins B, Guzman-Castillo M, Capewell S, O'Flaherty
- M, et al. Estimating the health and economic effects of the voluntary sodium reduction targets in
- 729 Brazil: microsimulation analysis. BMC medicine. 2021;19(1):1-10.
- 730 57. Shangguan S, Mozaffarian D, Sy S, Lee Y, Liu J, Wilde PE, et al. Health Impact and
- 731 Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary
- 732 Sugar Reduction Targets in the United States: A Micro-Simulation Study. Circulation. 2021.
- 733 58. Aminde LN, Wanjau MN, Cobiac LJ, Veerman JL. Estimated Impact of Achieving the
- Australian National Sodium Reduction Targets on Blood Pressure, Chronic Kidney Disease
- Burden and Healthcare Costs: A Modelling Study. Nutrients. 2023;15(2).
- 736 59. Aminde LN, Cobiac LJ, Phung D, Phung HN, Veerman JL. Avoidable burden of stomach
- cancer and potential gains in healthy life years from gradual reductions in salt consumption in
- 738 Vietnam, 2019–2030: A modelling study. Public Health Nutrition. 2023;26(3):586-97.

- 739 60. Aminde LN, Cobiac L, Veerman JL. Cost-effectiveness analysis of population salt
- reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling
- 741 study. BMJ open. 2020;10(11):e041346.
- 742 61. Trieu K, Coyle DH, Afshin A, Neal B, Marklund M, Wu JH. The estimated health impact
- of sodium reduction through food reformulation in Australia: A modeling study. PLoS Medicine.
- 744 2021;18(10):e1003806.
- 745 62. Trieu K, Coyle DH, Rosewarne E, Shahid M, Yamamoto R, Nishida C, et al. Estimated
- 746 Dietary and Health Impact of the World Health Organization's Global Sodium Benchmarks on
- Packaged Foods in Australia: a Modeling Study. Hypertension. 2023.
- 748 63. Pacheco C, Mullen KA, Coutinho T, Jaffer S, Parry M, Van Spall HGC, et al. The
- 749 Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and
- 750 Management of Cardiovascular Disease in Women Chapter 5: Sex- and Gender-Unique
- 751 Manifestations of Cardiovascular Disease. CJC Open. 2022;4(3):243-62.
- 752 64. Charlton KE, Corso B, Ware L, Schutte AE, Wepener L, Minicuci N, et al. Effect of
- 753 South Africa's interim mandatory salt reduction programme on urinary sodium excretion and
- blood pressure. Preventive medicine reports. 2021;23:101469.
- 755 65. World Health Organization. WHO global sodium benchmarks for different food
- 756 categories. Geneva: WHO;2021. [Available from:
- 757 https://www.who.int/publications/i/item/9789240025097.
- 758 66. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ,
- et al. Projected effect of dietary salt reductions on future cardiovascular disease. New England
- 760 Journal of Medicine. 2010;362(7):590-9.
- 761 67. Grieger JA, Johnson BJ, Wycherley TP, Golley RK. Evaluation of Simulation Models
- that Estimate the Effect of Dietary Strategies on Nutritional Intake: A Systematic Review. The
- 763 Journal of Nutrition. 2017;147(5):908-31.
- 764 68. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, et al. Cost
- 765 effectiveness of a government supported policy strategy to decrease sodium intake: global
- analysis across 183 nations. Bmj. 2017;356.
- 767 69. Kim J, Oh A, Truong H, Laszkowska M, Camargo MC, Abrams J, et al. Low sodium diet
- for gastric cancer prevention in the United States: Results of a Markov model. Cancer Medicine.
- 769 2020.

- 770 70. Kypridemos C, Guzman-Castillo M, Hyseni L, Hickey GL, Bandosz P, Buchan I, et al.
- Estimated reductions in cardiovascular and gastric cancer disease burden through salt policies in
- Figure 2017;7(1):e013791.
- 773 71. Park H-K, Lee Y, Kang B-W, Kwon K-i, Kim J-W, Kwon O-S, et al. Progress on sodium
- reduction in South Korea. BMJ Global Health. 2020;5(5):e002028.
- 775 72. Arcand J, Campbell NR. Dietary sodium reduction in Canada: more action is needed to
- reach the 2025 global targets. CMAJ. 2022;194(10):E387-E8.
- 777 73. Greer RC, Marklund M, Anderson CA, Cobb LK, Dalcin AT, Henry M, et al. Potassium-
- enriched salt substitutes as a means to lower blood pressure: benefits and risks. Hypertension.
- 779 2020;75(2):266-74.